Drugs / Lete-cel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03709706 | Dec 2018 → Jun 2022 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-06-01 | GlaxoSmithKline | Results GSK to showcase scientific advances and progress in oncology at ASCO and EHA gsk.com ↗
A presentation of note will include findings from an interim analysis on the safety and efficacy of lete-cel in myxoid/round cell liposarcoma (ASCO abstract #11521). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-06-01 | GlaxoSmithKline | GSK to showcase scientific advances and progress in oncology at ASCO and EHA gsk.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lete-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03709706 ↗ |